written on 10.03.2014

FDA Approves the First Drug Indicated for Lipodystrophy Complications


The FDA has approved the first replacement therapy for patients with lipodystrophy, a condition so devastating and rare it has been called an “ultra orphan” disease. Myalept (metreleptin) is indicated as an adjunct to diet in patients with congenital or acquired generalized lipodystrophy, to treat complications of leptin deficiency. The drug received approval on February […]